The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
TRENDS Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
-
BUSINESS Sumitomo Dainippon Going Full Tilt for Napabucasin Colorectal Cancer Trial after Pancreatic Flop
August 8, 2019
-
BUSINESS Novartis’ Entresto Filed in Japan for Chronic Heart Failure
August 7, 2019
-
BUSINESS Gearing Up for Japan Debut, Daiichi Sankyo Mounting Push for AML Med Vanflyta
August 6, 2019
-
REGULATORY MHLW Pharma Bureau Chief Keen on Early Enactment of PMD Amendment Bill
August 5, 2019
-
REGULATORY Tecentriq’s SCLC Use Gets MHLW Panel Nod for September Approval
August 5, 2019
-
REGULATORY MHLW Finalizing Timing to Announce Post-Oct. 1 NHI Prices, Bureau Chief Hints at August Possibility
August 2, 2019
-
BUSINESS Takeda Squeezes Projected Losses for FY2019 as Velcade Copy Lags
August 1, 2019
-
BUSINESS Crushing Defeat or Sign of Hope? Analyst, KOL Give Mixed Views for CheckMate-227
July 31, 2019
-
BUSINESS Mitsubishi Tanabe’s Sales Fall 6.9% as Gilenya Snafu Takes Toll
July 30, 2019
-
BUSINESS Nesp Biosame to Hit Japan Shelves on August 5
July 29, 2019
-
BUSINESS Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
-
REGULATORY Industry’s Plea to Scrap PMP Company Criteria Gets Cold Shoulder at Chuikyo
July 25, 2019
-
BUSINESS Ayumi to Ease Restrictions on Enbrel Biosimilar Use as Product Boost Progresses
July 24, 2019
-
REGULATORY 3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
-
BUSINESS Boehringer Said to Consider Nixing Allowances for Some Wholesalers, Denies Intention to Narrow Distributors
July 23, 2019
-
REGULATORY MHLW Panel to Review Tecentriq’s SCLC Use and More for September OK
July 23, 2019
-
BUSINESS Nitto Pharma Accelerating Development of Gut Bacteria Drugs, Eyes Clinical Studies within 3 Years
July 22, 2019
-
ORGANIZATION Experts Talk over Biosimilar Challenges, Chide Unstable Supplies and Indication Gaps
July 19, 2019
-
BUSINESS IPO Pending, StemRIM Looks to File World’s 1st Regeneration-Inducing Med Next Year: CEO
July 18, 2019
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…